118 filings
Page 4 of 6
8-K
6irehwe92gw3f2uz
13 Jan 20
Regulation FD Disclosure
7:17am
8-K
29d8udu8bh9w62oc
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
8-K
b6jw o9j4
6 Nov 19
Zafgen Reports Third Quarter 2019 Financial Results
4:30pm
8-K
vapsctwus e7cy8ab5c
19 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
iq9n 8g27jk5g
12 Sep 19
Cost Associated with Exit or Disposal Activities
5:19pm
8-K
2cot41ddbg0n
8 Aug 19
Zafgen Reports Second Quarter 2019 Operating and Financial Results
4:32pm
8-K
1xew2m7n62q4k1l2ap6e
13 Jun 19
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
ld8tctxdcex
30 May 19
Zafgen Announces Regulatory Update onZGN-1061
7:21am
8-K
wb0qpixrdoru07
9 May 19
Zafgen Reports First Quarter 2019 Operating and Financial Results
4:26pm
8-K
63v kptr9vy4
4 Apr 19
Other Events
4:47pm
8-K
zi8i 2e6dxarj8ym
11 Mar 19
Results of Operations and Financial Condition
4:12pm
8-K
5gt490whjwf0
15 Feb 19
Entry into a Material Definitive Agreement
5:00pm
8-K
ucqoghxhaz x68rpcn
17 Jan 19
Zafgen Announces Positive Results for Second Cohort
7:30am
8-K
al4q57s6
26 Nov 18
Zafgen Provides Update on Investigational New Drug Application forZGN-1061
7:17am
8-K
dks3frt lvkb
9 Nov 18
Entry into a Material Definitive Agreement
5:10pm
8-K
py2a 1npuf
7 Nov 18
Zafgen Reports Third Quarter 2018 Operating and Financial Results
4:15pm
8-K
8k82zgld8eboqdu60
7 Aug 18
Zafgen Reports Second Quarter 2018 Operating and Financial Results
4:21pm
8-K
bbjpvd
2 Aug 18
Zafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes
4:24pm
8-K
d6x70b
28 Jun 18
Zafgen Announces Proposed Offering of Common Stock
5:01pm
8-K
z2s4jw
25 Jun 18
Zafgen Announces Positive Full Results in Phase 2Proof-of-Concept Trial ofZGN-1061 in Patients withDifficult-to-Control Type 2 Diabetes
7:15am